329 related articles for article (PubMed ID: 9915269)
1. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
Gunnell J; Yeun JY; Depner TA; Kaysen GA
Am J Kidney Dis; 1999 Jan; 33(1):63-72. PubMed ID: 9915269
[TBL] [Abstract][Full Text] [Related]
2. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
3. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.
Wei M; Bargman JM; Oreopoulos DG
Int Urol Nephrol; 2007; 39(3):935-40. PubMed ID: 17534732
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
5. Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease.
Góes MA; Dalboni MA; Manfredi SR; Cendoroglo MS; Batista MC; Canziani ME; Balakrishnan VS; Pereira BJ; Draibe SA; Cendoroglo M
Clin Nephrol; 2010 Jan; 73(1):7-13. PubMed ID: 20040346
[TBL] [Abstract][Full Text] [Related]
6. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
8. Inflammation, peritoneal transport, and response to erythropoietin in peritoneal dialysis patients.
Pilkey RM; Morton AR; Iliescu EA
Adv Perit Dial; 2001; 17():153-7. PubMed ID: 11510266
[TBL] [Abstract][Full Text] [Related]
9. Hemodialysis treatment time versus erythropoietin dose requirement: Reduction in 2,000 units per week by extension of hemodialysis for 1 hour
.
Maeda A; Tsuruya K; Maeda M; Yamasaki M; Nakashima A; Nakashima Y; Date S; Maeda T; Kamijyou M; Kubara T; Hayashi W; Kitazono T
Clin Nephrol; 2019 Oct; 92(4):174-179. PubMed ID: 31272526
[TBL] [Abstract][Full Text] [Related]
10. Predictors of erythropoietin responsiveness in chronic hemodialysis patients.
Tonelli M; Blake PG; Muirhead N
ASAIO J; 2001; 47(1):82-5. PubMed ID: 11199321
[TBL] [Abstract][Full Text] [Related]
11. The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis.
Kim JK; Park BS; Park MJ; Choi W; Ma SK; Nah MY; Yeum CH; Jung K; Lee SC; Kim SW; Kim NH; Kang YJ; Choi KC
Korean J Intern Med; 2001 Jun; 16(2):110-7. PubMed ID: 11590897
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
13. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
14. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
Hutchinson FN; Jones WJ
Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
[TBL] [Abstract][Full Text] [Related]
17. Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection.
Altintepe L; Kurtoglu E; Tonbul Z; Yeksan M; Yildiz A; Türk S
Clin Nephrol; 2004 May; 61(5):347-51. PubMed ID: 15182130
[TBL] [Abstract][Full Text] [Related]
18. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
19. Trends in anemia management among US hemodialysis patients.
Coladonato JA; Frankenfield DL; Reddan DN; Klassen PS; Szczech LA; Johnson CA; Owen WF
J Am Soc Nephrol; 2002 May; 13(5):1288-95. PubMed ID: 11961017
[TBL] [Abstract][Full Text] [Related]
20. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.
Bárány P; Divino Filho JC; Bergström J
Am J Kidney Dis; 1997 Apr; 29(4):565-8. PubMed ID: 9100046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
